Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Stock analysts at Piper Jaffray Companies decreased their Q4 2018 EPS estimates for shares of Ionis Pharmaceuticals in a report released on Tuesday, November 6th. Piper Jaffray Companies analyst T. Van. Buren now anticipates that the company will earn $0.23 per share for the quarter, down from their prior forecast of $0.32. Piper Jaffray Companies has a “Hold” rating and a $50.00 price target on the stock. Piper Jaffray Companies also issued estimates for Ionis Pharmaceuticals’ FY2019 earnings at $0.35 EPS, FY2021 earnings at $3.00 EPS and FY2022 earnings at $4.55 EPS.
Other analysts also recently issued research reports about the stock. ValuEngine raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Morgan Stanley decreased their price target on shares of Ionis Pharmaceuticals from $49.00 to $45.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 28th. Stifel Nicolaus reduced their price objective on shares of Ionis Pharmaceuticals from $55.00 to $48.00 and set a “hold” rating for the company in a research note on Tuesday, August 7th. Finally, Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $53.86.
Ionis Pharmaceuticals stock opened at $53.65 on Wednesday. The company has a quick ratio of 8.34, a current ratio of 8.38 and a debt-to-equity ratio of 0.76. Ionis Pharmaceuticals has a fifty-two week low of $39.07 and a fifty-two week high of $57.92. The company has a market cap of $7.10 billion, a PE ratio of 670.63 and a beta of 2.39.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, November 6th. The company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.13. Ionis Pharmaceuticals had a negative net margin of 7.20% and a negative return on equity of 1.22%. The firm had revenue of $145.40 million during the quarter, compared to the consensus estimate of $146.77 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The company’s revenue was up 22.9% on a year-over-year basis.
In other Ionis Pharmaceuticals news, COO Brett P. Monia sold 16,493 shares of Ionis Pharmaceuticals stock in a transaction on Monday, August 27th. The shares were sold at an average price of $54.00, for a total value of $890,622.00. Following the transaction, the chief operating officer now directly owns 24,834 shares of the company’s stock, valued at $1,341,036. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP C Frank Bennett sold 12,500 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $49.54, for a total transaction of $619,250.00. Following the completion of the transaction, the senior vice president now directly owns 31,896 shares in the company, valued at $1,580,127.84. The disclosure for this sale can be found here. 2.44% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. TRUE Private Wealth Advisors bought a new stake in Ionis Pharmaceuticals in the 3rd quarter valued at $133,000. Rockefeller Capital Management L.P. bought a new position in Ionis Pharmaceuticals in the second quarter valued at about $156,000. Parallel Advisors LLC raised its position in Ionis Pharmaceuticals by 195.5% in the third quarter. Parallel Advisors LLC now owns 3,023 shares of the company’s stock valued at $156,000 after purchasing an additional 2,000 shares during the last quarter. Clarus Wealth Advisors raised its position in Ionis Pharmaceuticals by 200.0% in the third quarter. Clarus Wealth Advisors now owns 3,600 shares of the company’s stock valued at $186,000 after purchasing an additional 2,400 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Ionis Pharmaceuticals in the second quarter valued at about $212,000. 86.35% of the stock is currently owned by institutional investors and hedge funds.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.